Gastroenterology

Volume 163 / Number 5 November 2022 www.gastrojournal.org

TABLE OF CONTENTS

Contents

ON THE COVER

Identification of Quiescent LGR5$^+$ Stem Cells in the Human Colon. **See article by Ishikawa et al, page 1391, for additional information.**

IN MEMORIAM

1135 In Memoriam—Hugo R. Rosen
N. Terrault, V. H. Shah, and T. Heller

COMMENTARY

1137 Heterogeneity in Efficacy and Safety Endpoints for Pediatric Clinical Trials in Inflammatory Bowel Disease: A Need for Harmonization (WWW)
E. Crowley, A. M. Griffiths, and V. Jairath, pIBD CLINICAL TRIALS OUTCOME GROUP

DIVERSITY, EQUITY, AND INCLUSION IN GI

1145 Identifying Care Challenges as Opportunities for Research and Education in Inflammatory Bowel Disease in South Asia
M. Balasubramaniam, N. Nandi, T. Aswani-Omprakash, S. Sebastian, V. Sharma, and P. Deepak, South Asian IBD Alliance Board Of Directors

MENTORING, EDUCATION, AND TRAINING CORNER

1151 Growing Your Niche Practice
J. Korman and T. Qazi

EDITORIALS

1155 Promise and Perils of Blood-based Signatures for Detecting Early-Onset Colorectal Cancer
S. Singh and S. Gupta
See Nakamura K et al on page 1242.

1157 Early Detection of Pancreatic Cancer: Are We Ready for Prime Time?
W. Wu
See Nakamura K et al on page 1252.

(V) Video (CGH) Related article in *CGH* Hot Papers From New Investigators

(CME) CME quiz (E) Editorial accompanies this article (WWW) Additional online content available (COV) Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA. 2022 US subscription rates: individual, $739.00; student and resident, $282.00. Outside of the U.S. and possessions: individual, $968.00; student and resident, $562.00; surface delivery, no additional charge; air mail delivery, add $78.00. Prices subject to change without notice.

1159 **Delivering a Double Whammy: Targeting Stroma to Improve Immunotherapy Outcomes in Pancreatic Ductal Adenocarcinoma**
S. Lavania
See Blair AB et al on page 1267.

1161 **Nutrient Scavenging From Muscle Cells: A Survival Strategy of Pancreatic Cancer Cells Ends Cachexia**
I. Regel and J. Mayerle
See Zhou Z et al on page 1281.

1164 **Fatigue in Inflammatory Bowel Disease: A Common Complaint With Few Answers**
J. Pekow
See Truyens ML et al on page 1294.

1166 **The Pediatric Inflammatory Crohn's Magnetic Resonance Enterography Index: A Step Forward for Transmural Pediatric Crohn's Disease Monitoring and Healing**
M. T. Dolinger and M. C. Dubinsky
See Focht G et al on page 1306.

1168 **Are We Ready to Embrace Endoscopic Submucosal Dissection as the Organ-Sparing, Minimally Invasive Endoscopic Surgical Procedure of Choice for Large Colorectal Adenoma and Early Cancers?**
K. Mönkemüller and J. J. Vargo
See Ohata K et al on page 1423.

1170 **A Growing Hope for Earlier Detection of Pancreatic Cancer**
M. Rosenthal, K. Schawkat, and B. Wolpin
See Mukherjee S et al on page 1435.

GASTROENTEROLOGY IN MOTION

1173 **Gastroplasty With Endoscopic Myotomy (GEM) for the Treatment of Obesity: Preliminary Efficacy and Physiologic Results**
C. C. Thompson, P. Jirapinyo, R. Shah, and C. Simsek

CLINICAL CHALLENGES AND IMAGES IN GI

1176 **Painless Rectal Bleeding in a Patient With Prostate Cancer**
S. P. Medina, A. C. Wong, and N. El-Nachef

1179 **An Unusual Cause of Rectal Pain**
H. W. Leow, A. Coupland, and N. T. Ventham

ELECTRONIC CLINICAL CHALLENGES AND IMAGES IN GI

For a full list, please see the table of contents online at www.gastrojournal.org.

PRACTICAL TEACHING CASES

1183 **Target Sign and Abdominal Pain: An Approach to Diagnosis and Treatment**
P. Zargar, S. Gandhi, and V. S. Kotwal

1186 **An Unusual Complication of Endoscopic Cyanoacrylate Injection for Gastric Varix**
T. Prasoppokakorn and R. Rerknimitr

BRIEF REVIEW

1188 **Recent Advances in the Study of Extracellular Vesicles in Colorectal Cancer**
S. E. Glass and R. J. Coffey

GUIDELINES

1198 **AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity**
E. Grunvald, R. Shah, R. Hernaez, A. K. Chandar, O. Pickett-Blakely, L. M. Teigen, T. Harindhanavudhi, S. Sultan, S. Singh, and P. Davitkov, on behalf of the AGA Clinical Guidelines Committee

1226 **Clinical Decision Support Tool: Pharmacological Interventions for Adults With Obesity**

1227 **Spotlight: Pharmacological Interventions in the Management of Obesity in Adults**
O. Pickett-Blakely, P. Davitkov, E. Grunvald, S. Singh, R. Shah, R. Hernaez, A. K. Chandar, L. M. Teigen, T. Harindhanavudhi, and S. Sultan

ORIGINAL RESEARCH

Full Reports

Esophagus

1228 **The Ephrin B2 Receptor Tyrosine Kinase Is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett's Neoplasia**
S. Venkitachalam, D. Babu, D. Ravillah, R. M. Katabathula, P. Joseph, S. Singh, B. Udhayakumar, Y. Miao, O. Martinez-Uribe, J. A. Hogue, A. M. Kresak, D. Dawson, T. LaFramboise, J. E. Willis, A. Chak, K. S. Garman, A. E. Blum, V. Varadan, and K. Guda

Esophageal adenocarcinoma is an aggressive cancer that develops from precursor Barrett's esophagus. We identify the EphB2 pathway as a potential promoter of Barrett's esophagus and associated cancer, uncovering new chemopreventive/therapeutic avenues.

GI Cancer

1242 **A Liquid Biopsy Signature for the Detection of Patients With Early-Onset Colorectal Cancer**
K. Nakamura, G. Hernández, G. G. Sharma, Y. Wada, J. K. Banwait, N. González, J. Perea, F. Balaguer, H. Takamaru, Y. Saito, Y. Toiyama, Y. Kodera, C. R. Boland, L. Bujanda, E. Quintero, and A. Goel

See editorial on page 1155.

Our blood-based circulating micro RNA signature has the potential to identify patients with early-onset colorectal cancer with high accuracy and offers a clinical tool for early diagnosis and population screening of patients suffering from this malignancy.

1252 **An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study**
K. Nakamura, Z. Zhu, S. Roy, E. Jun, H. Han, R. M. Munoz, S. Nishiwada, G. Sharma, D. Cridebring, F. Zenhausern, S. Kim, D. J. Roe, S. Darabi, I.-W. Han, D. B. Evans, S. Yamada, M. J. Demeure, C. Becerra, S. A. Celinski, E. Borazanci, S. Tsai, Y. Kodera, J. O. Park, J. S. Bolton, X. Wang, S. C. Kim, D. Von Hoff, and A. Goel

See editorial on page 1157.

Our exosome-based transcriptomic signature that combines cell-free and exosomal microRNAs has the potential to identify patients with pancreatic ductal adenocarcinoma with high diagnostic accuracy, and offers an important noninvasive assay for early detection of this fatal malignancy.

1267 **Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy**
A. B. Blair, J. Wang, J. Davelaar, A. Baker, K. Li, N. Niu, J. Wang, Y. Shao, V. Funes, P. Li, J. A. Pachter, D. C. Maneval, F. Dezem, J. Plummer, K. S. Chan, J. Gong, A. E. Hendifar, S. J. Pandol, R. Burkhart, Y. Zhang, L. Zheng, and A. Osipov

See editorial on page 1159.

Simultaneous targeting of both intracellular and extracellular components of the stroma in pancreatic cancer can alter the tumor microenvironment, thereby improving immunotherapy response.

1281 **Acetyl-Coenzyme A Synthetase 2 Potentiates Macropinocytosis and Muscle Wasting Through Metabolic Reprogramming in Pancreatic Cancer**
Z. Zhou, Y. Ren, J. Yang, M. Liu, X. Shi, W. Luo, K.-M. Fung, C. Xu, M. S. Bronze, Y. Zhang, C. W. Houchen, and M. L.
See editorial on page 1161.

ACSS2 promotes macropinocytosis and muscle wasting through ETV4/ZIP4-mediated metabolic reprogramming, which provides additional nutrients to support tumor growth in pancreatic cancer.

Inflammatory Bowel Disease

1294 **Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled Trial**
M. Truyens, T. Lobatón, M. Ferrante, P. Bossuyt, S. Vermeire, L. Pouillon, P. Dewint, A. Cremer, H. Peeters, G. Lambrecht, E. Louis, J.-F. Rahier, O. Dewit, V. Muls, T. Holvoet, L. Vandermeulen, A. Peeters, G. B. Gonzales, S. Bos, D. Laukens, and M. De Vos
See editorial on page 1164.

This multicentered study shows that oral intake of 5-hydroxytryptophan is not better than placebo in the treatment of fatigue in patients with inflammatory bowel diseases.

1306 **Development, Validation, and Evaluation of the Pediatric Inflammatory Crohn's Magnetic Resonance Enterography Index From the ImageKids Study**
G. Focht, R. Cytter-Kuint, M.-L. C. Greer, L.-T. Pratt, D. A. Castro, P. C. Church, T. D. Walters, J. Hyams, D. Navon, J. Martin de Carpi, F. Ruemmele, R. K. Russell, M. Gavish, A. M. Griffiths, and D. Turner
See editorial on page 1166.

We have developed a validated score, called the Pediatric Inflammatory Crohn's Magnetic Resonance Enterography Index, which quantifies the degree of inflammation in the bowel of children with Crohn's disease, as measured using magnetic resonance imaging of the bowel.

Intestinal Inflammation

1321 **Clinical Manifestations and Stool Load of Atypical Enteropathogenic *Escherichia coli* Infections in United States Children and Adults**
S. E. Kralicek, L. M. Sitaraman, P. V. Kuprys, A. T. Harrington, B. Ramakrishna, M. Osman, and G. A. Hecht

Atypical enteropathogenic *Escherichia coli* causes a wide array of symptoms, ranging from asymptomatic carriage to severe, prolonged diarrhea, often with vomiting, abdominal pain, or fever. Higher stool loads are associated with symptoms.

1334 **SMAD4 Suppresses Colitis-associated Carcinoma Through Inhibition of CCL20/CCR6-mediated Inflammation**
D. N. Hanna, P. M. Smith, S. V. Novitskiy, M. K. Washington, J. Zi, C. J. Weaver, J. A. Hamaamen, K. B. Lewis, J. Zhu, J. Yang, Q. Liu, R. D. Beauchamp, and A. L. Means

The SMAD4 tumor suppressor gene regulates communication between colon cells and surrounding immune cells. In the setting of colitis, SMAD4 loss leads to increased immune cells and promotes tumor development.

Gut Microbiota

1351 **Biogeographic Variation and Functional Pathways of the Gut Microbiota in Celiac Disease**
M. Constante, J. Libertucci, H. J. Galipeau, J. C. Szamosi, G. Rueda, P. M. Miranda, M. I. Pinto-Sanchez, C. M. Southward, L. Rossi, M. E. Fontes, F. G. Chirdo, M. G. Surette, P. Bercik, A. Caminero, and E. F. Verdu

In celiac disease, bacterial composition and function differ according to gut location.

1364 **Altered Gut Microbiome Composition and Function Are Associated With Gut Barrier Dysfunction in Healthy Relatives of Patients With Crohn's Disease**
H. Leibovitzh, S.-H. Lee, M. Xue, J. A. Raygoza Garay, C. Hernandez-Rocha, K. L. Madsen, J. B. Meddings, D. S. Guttman, O. Espin-Garcia, M. I. Smith, A. Goethel, A. M. Griffiths, P. Moayyedi, A. H. Steinhart, R. Panaccione, H. Q. Huynh, K. Jacobson, G. Aumais, D. R. Mack, M. T. Abreu, C. N. Bernstein, J. K. Marshall, D. Turner, W. Xu, The CCC GEM Project Research Consortium, W. Turpin, and K. Croitoru

Alterations in gut microbiome are associated with gut barrier dysfunction in healthy humans.

1377 **Histone Deacetylase Inhibition by Gut Microbe-Generated Short-Chain Fatty Acids Entrains Intestinal Epithelial Circadian Rhythms**
J. A. Fawad, D. H. Luzader, G. F. Hanson, T. J. Moutinho Jr, C. A. McKinney, P. G. Mitchell, K. Brown-Steinke, A. Kumar, M. Park, S. Lee, D. T. Bolick, G. L. Medlock, J. Y. Zhao, A. E. Rosselot, C. J. Chou, E. M. Eshleman, T. Alenghat, C. I. Hong, J. A. Papin, and S. R. Moore

Circadian timekeeping in intestinal organoids is reset by gut microbe-generated short-chain fatty acids through an epigenetic mechanism of histone deacetylases inhibition.

Colon

1391 **Identification of Quiescent LGR5$^+$ Stem Cells in the Human Colon**
K. Ishikawa, S. Sugimoto, M. Oda, M. Fujii, S. Takahashi, Y. Ohta, A. Takano, K. Ishimaru, M. Matano, K. Yoshida, H. Hanyu, K. Toshimitsu, K. Sawada, M. Shimokawa, M. Saito, K. Kawasaki, R. Ishii, K. Taniguchi, T. Imamura, T. Kanai, and T. Sato

Tissue engineering technology revealed that human colonic stem cells are slow-cycling and resistant to chemotherapy, which challenges the current understanding of mucosal regeneration based on mouse-centered research.

Pancreas

1407 **Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis**
U. M. Mahajan, B. Oehrle, S. Sirtl, A. Alnatsha, E. Goni, I. Regel, G. Beyer, M. Vornhülz, J. Vielhauer, A. Chromik, M. Bahra, F. Klein, W. Uhl, T. Fahlbusch, M. Distler, J. Weitz, R. Grützmann, C. Pilarsky, F. U. Weiss, M. G. Adam, J. P. Neoptolemos, H. Kalthoff, R. Rad, N. Christiansen, B. Bethan, B. Kamlage, M. M. Lerch, and J. Mayerle

The m-Metabolic signature, based on just 4 plasma analytes combined with serum carbohydrate antigen 19-9, is highly accurate in diagnosing pancreatic cancer and could contribute to earlier treatment and improved prognosis of patients with pancreatic cancer.

Endoscopy

1423 **Long-term Outcomes After Endoscopic Submucosal Dissection for Large Colorectal Epithelial Neoplasms: A Prospective, Multicenter, Cohort Trial From Japan**
K. Ohata, N. Kobayashi, E. Sakai, Y. Takeuchi, A. Chino, H. Takamaru, S. Kodashima, K. Hotta, K. Harada, H. Ikematsu, T. Uraoka, T. Murakami, S. Tsuji, T. Abe, A. Katagiri, S. Hori, T. Michida, T. Suzuki, M. Fukuzawa, S. Kiriyama, K. Fukase, Y. Murakami, H. Ishikawa, and Y. Saito

See editorial on page 1168.

Accurate histologic assessment facilitated by endoscopic submucosal dissection enables stratification of the risk of lymph node metastasis and determines the necessity of additional surgery, which may have led to a good long-term prognosis.

Artificial Intelligence

1435 **Radiomics-based Machine-learning Models Can Detect Pancreatic Cancer on Prediagnostic Computed Tomography Scans at a Substantial Lead Time Before Clinical Diagnosis**
S. Mukherjee, A. Patra, H. Khasawneh, P. Korfiatis, N. Rajamohan, G. Suman, S. Majumder, A. Panda, M. P. Johnson, N. B. Larson, D. E. Wright, T. L. Kline, J. G. Fletcher, S. T. Chari, and A. H. Goenka

See editorial on page 1170.

Artificial intelligence can detect pancreas cancer on computed tomography well before its detection by radiologists and before the onset of cancer symptoms when surgical cure is a possibility.

RESEARCH LETTERS

1447 **Diagnostic Performance of a Noninvasive Breath Test for Colorectal Cancer: COBRA1 Study**
G. Woodfield, I. Belluomo, I. Laponogov, K. Veselkov, COBRA1 WORKING GROUP, A. J. Cross, and G. B. Hanna

1450 **A Lesson in Transcriptional Plasticity: Classical Identity Is Silenced, but Not Lost, in Pancreatic Ductal Adenocarcinoma Cell Lines**
T. Baba, P. Finetti, Pancreatic Cancer Group, K. D. Lillemoe, A. L. Warshaw, C. Fernández-Del Castillo, and A. S. Liss

1454 **Treatment of Women With Hepatitis C Diagnosed in Pregnancy: a Co-Located Treatment Approach**
T. Kushner, M. Lange, R. Sperling, and D. Dieterich

1457 **HNF4A Defines Molecular Subtypes and Vulnerability to Transforming Growth Factor β-Pathway Targeted Therapies in Cancers of the Distal Esophagus**
A. E. Blum, D. Ravillah, Betrnet Consortium, R. M. Katabathula, S. Khalighi, V. Varadan, and K. Guda

CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

e33 **CME Exam 1: An Unusual Complication of Endoscopic Cyanoacrylate Injection for Gastric Varix**

e35 **CME Exam 2: Long-term Outcomes After Endoscopic Submucosal Dissection for Large Colorectal Epithelial Neoplasms: A Prospective, Multicenter, Cohort Trial From Japan**

CLINICAL PRACTICE UPDATE

1461 **AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review**
P. H. R. Green, S. Paski, C. W. Ko, and A. Rubio-Tapia

GASTRO DIGEST

1470 **Risankizumab for Induction and Maintenance of Remission in Crohn's Disease**
R. Khanna

1471 **More Precision in Adjuvant Chemotherapy for Stage II Colon Cancer Using Liquid Biopsy After Surgery**
V. Sallinen

1472 **Targeting De Novo Lipogenesis by Different Approaches Shows Promise in Nonalcoholic Steatohepatitis**
B. DeBosch

1473 **Correction**